

Build innovation capacity and develop pipeline of homegrown products: Case of the mRNA Hub in South Africa



- **Relevant COVID investments:**
 - Immunology (NICD, UCT, UKZN)
 - Genomics (KRISP, UCT)
 - Vaccines (Wits, NICD, Sisonke)
 - AGTRU (Wits – EMU)
 - PUDAC
- Project speaks directly to the SAMRC mandate to address priority health issues in SA and beyond, to build innovation capacity and to develop a pipeline of homegrown products
- Objective 3 is aimed at ensuring maximum participation of SA and other African countries in developing & testing context-appropriate and a **sustainable** product pipeline
- Leveraging off existing SAMRC/DSI investments and technical expertise in SA (genomics, immunology, vaccine platforms and clinical) to feed the pipeline for local manufacturing

